ArticleProbiotics and antimicrobial proteins2026
A Novel Indigenous Probiotic, Clostridium moniliforme G18, Confers Health Benefits to Mud Crabs (Scylla paramamosain).
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Butyrate-producing bacteria (BPB) are widely used as additives in aquaculture because of the beneficial effects of the butyrate they produce. However, most available BPB currently are of terrestrial origin, which are quite different from aquatic animals, resulting in profoundly unstable probiotic performance. This study isolated a novel, indigenous BPB, Clostridium moniliforme G18, from the gut of mud crabs, Scylla paramamosain. The strain demonstrated robust butyric acid production, tolerance to gastrointestinal conditions (pH 4-9, 0-3% NaCl, 0.4-1.0% bile salts), antibiotic sensitivity, pathogen inhibition, and non-hemolytic activity. Dietary supplementation with G18 alone or in combination with resistant starch and galactooligosaccharides (GR18) significantly enhanced mud crab body weight (P < 0.05). The supplementation improved intestinal health by enhancing histomorphology and upregulating tight junction genes (ZO-1 and Claudin). Furthermore, it boosted antioxidant capacity (elevated SOD and CAT; reduced MDA), modulated immune responses (increased AKP and ACP; reduced ALT and AST, P < 0.05), and increased intestinal butyrate levels. Analysis of the gut microbiota of mud crabs fed G18 alone or in combination with prebiotics revealed an increase in alpha diversity and beneficial composition changes (including reduced Vibrionaceae and elevated Proteocatella, P < 0.05). Following Vibrio parahaemolyticus challenge, mud crabs fed G18 and GR18 showed significantly higher survival rate (66.7% and 73.3%, respectively, P < 0.05) versus 53.3% in the control group. These diets mitigated intestinal damage, restored immune and antioxidant parameters, and enhanced the expression of barrier function genes. These results establish indigenous C. moniliforme G18 as a highly promising probiotic candidate for enhancing growth and health in mud crabs.
Indexed as
Identifiers
41817894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.